Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
3 results
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
Lancet Neurol. 2017 Jul;16(7):505-512. doi: 10.1016/S1474-4422(17)30115-1. Epub 2017 May 15.
Lancet Neurol. 2017.
PMID: 28522181
Clinical Trial.
Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP.
WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP.
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269.
Amyotroph Lateral Scler Frontotemporal Degener. 2017.
PMID: 28872920
Clinical Trial.
Item in Clipboard
Edaravone for treatment of early-stage ALS - Authors' reply.
Akimoto M, Nakamura K; Writing Group on behalf of the Edaravone (MCI-186) ALS 19 Study Group.
Akimoto M, et al.
Lancet Neurol. 2017 Oct;16(10):772. doi: 10.1016/S1474-4422(17)30290-9. Epub 2017 Sep 12.
Lancet Neurol. 2017.
PMID: 28920878
No abstract available.
Item in Clipboard
Cite
Cite
ARTICLE TYPE
ARTICLE LANGUAGE
AGE
Filters on the sidebar will be reset to the default list and any currently applied filters will be cleared.